Radiopharm Theranostics Ltd (ASX:RAD) welcomes the publication of positive imaging data on its HER2 nanobody RAD201 in the prestigious European Journal of Nuclear Medicine & Molecular Imaging.
The publication indicated that RAD201 had a favourable biodistribution and showed high accumulation in all active HER2-positive tumour sites.
Favourable tumour targeting
It demonstrated a high target-to-background ratio, favourable tumour targeting and rapid blood clearance.
The publication also supported previous data regarding the safety profile for use of RAD201 in humans and highlighted that RAD201 is a “promising non-invasive tool for discriminating HER2 status in metastatic (breast) cancer, regardless of ongoing HER2-targeted antibody treatment”.
This is made possible due to RAD201’s ability to bind to a different part of the HER2 receptor.
The full publication is available to view here.
RAD chief executive officer and managing director Riccardo Canevari said: “This is an outstanding endorsement of our RAD201 technology that gives us added confidence to develop this asset even further.
“HER2 positive breast cancer is around 15-20% of all breast cancer cases, is particularly aggressive and hence has a higher mortality rate. Any new imaging or therapeutic solutions that can make a difference for this disease are highly sought after.”